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Introduction 
According to the World Health Organization, unipolar major 
depression is set to become the leading cause of disease 
burden by 2030. Major depressive disorder, or MDD, is a 
syndrome hallmarked by a persistent low mood and/or lack 
of enjoyment in previously pleasurable activities. Typically, 
onset occurs from 20-30 years and is often episodic in 
nature, occurring throughout the patient’s lifespan. MDD 
may also present in childhood or in older adulthood.
It is difficult for laypersons and general practitioners to 
differentiate  between a “normal” depressed mood and 
MDD. If a patient has just been diagnosed with cancer, his 
or her depression is an understandable reaction. On the 
other hand, given the enormous distress and impairment 
associated with depression, and the availability of safe and 
effective treatments, perhaps clinicians should have a low 
threshold for diagnosis.
General practitioners are frequently required to diagnose 
and manage MDD in the primary care setting, often in the 
context of other medical conditions. This article aims to 
provide clinicians with an approach to MDD that covers 
important aspects of differential diagnosis, co-morbidity, 
pharmacological treatment and special groups.
Epidemiology and burden of disease
According to the South African Stress and Health (SASH) 
study that was conducted between 2002-2004, South 
Africans have a 9.7% lifetime prevalence of MDD.1 MDD is 
a disabling condition and when undiagnosed or untreated, 
can result in significant costs to patients, their families and 
society at large. The negative consequences of depression 
include suicide, increased medical morbidity and mortality, 
workplace absenteeism and occupational and social 
dysfunction.2 
Making a diagnosis of major depression
Symptoms of depression include a sad or low mood that lasts 
for a minimum of two weeks and/or significant anhedonia 
(the absence of pleasure or the ability to experience it).3 In 
addition, appetite or weight change, sleep disturbances, 
restlessness, fatigue, feelings of guilt or worthlessness, 
impaired concentration and suicidal ideation may form 
part of the clinical presentation. At least five of the above 
symptoms need to be present to confirm the syndrome.
The boundary between normal sadness and major 
depression is ultimately defined by a careful history, 
focusing on the severity of symptoms and their associated 
distress and impairment. Closely related syndromes include 
bereavement, post-partum depression, premenstrual 
dysphoric disorder and adjustment disorders. There is a 
range of well-validated depression scales that can quickly 
provide a very useful measure of symptom severity for 
clinicians who prefer objective indicators of severity. These 
scales are also important in monitoring the response to 
intervention.
It is essential to enquire about previous episodes of mania 
or hypomania (defined as a distinct period of elevated or 
irritable mood, coupled with a decreased need for sleep, 
talkativeness, grandiosity and increased goal-directed 
behaviour), in order to exclude a possible bipolar illness. As 
part of the diagnostic process, exclusion of an underlying 
substance use disorder or medical condition is essential 
and should be guided by both the history and examination.
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Abstract
One in ten South Africans will be diagnosed with major depressive disorder (MDD) at some point in their lives. MDD is a 
potentially disabling condition that affects many spheres of an individual’s life and leads to marked social and occupational 
dysfunction. General practitioners are frequently required to diagnose and manage MDD, often in a time-pressured primary 
healthcare setting. This article aims to provide practitioners with an overview of MDD. It covers aspects of diagnosis, 
co-morbidity, pharmacology and special patient groups.
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Co-morbidity and depression
MDD is frequently associated with a variety of medical and 
psychiatric co-morbidities. 
Firstly, although the mechanism is not well understood, 
increased rates of MDD are associated with ischaemic 
heart disease (IHD), hypertension, stroke, dementia, 
obesity and metabolic syndrome. In addition, the presence 
of MDD in the context of the above illnesses significantly 
worsens their course and prognosis. Proposed contributory 
factors include detrimental lifestyle choices as a result of 
depression, e.g. smoking and drinking, as well as an altered 
physiological response to stress.4 
Secondly, psychiatric co-morbidity is prominent in the 
context of MDD and occurs in up to three quarters of 
individuals.5 It is notable that anxiety disorders often 
precede MDD. This emphasises the importance of treating 
anxiety disorders early. Substance use-disorders often 
begin after MDD, sometimes as a way of self-medicating a 
depressed mood. 
Neurobiology of depression
MDD is a notably heterogeneous condition, of which 
the neurobiology is still not well understood. Advances 
in genetics and neuroimaging continue to enhance 
understanding of this disease construct, which is likely to 
be the result of a complex interaction between multiple 
genes and environmental factors. Multiple neurocircuits 
and neurochemicals are thought to be involved in the 
pathogenesis of MDD and lead to a range of associated 
symptoms and disease subtypes.6 
Management of depression in general 
practice
For the purposes of this article, the approach to managing 
MDD has been divided into three sections, namely acute or 
short-term, intermediate and long-term management.
Acute or short-term management
Once the diagnosis of MDD has been made and any 
contributory or underlying medical conditions have been 
actively managed, several steps should be taken to ensure 
both the safety and optimum management of the patient. A 
suicide-risk assessment is of paramount importance in the 
management of all depressed patients. Many individuals 
will not willingly volunteer suicidal thoughts or plans, due 
to feelings of shame and fears of stigma. The suicide-risk 
assessment involves identifying and weighing up high-risk 
patient factors vs. individual protective factors (Table I).
Suicide assessment cannot be reduced to an arithmetic 
exercise. Clinicians are cautioned against weighing up the 
factors against one another in order to “cancel out” risk. 
At any point, if there is uncertainty about the suicide risk 
involved, clinicians are advised to err on the side of caution 
and to seek a second opinion from a colleague or mental 
health professional. Patients who are psychotic or actively 
suicidal and show intent to commit suicide constitute a high-
risk to themselves and may require involuntary admission to 
a psychiatric hospital according to the Mental Health Care 
Act of 2002. 
Once safety has been established, a comprehensive 
treatment plan, tailored according to individual needs, should 
be made in collaboration with the patient. Psychoeducation 
is a fundamental component of management and should 
be administered at each contact point. Target symptoms, 
previous response to treatment, choice of therapy, follow-
up plan and duration of treatment should all be documented 
in the treatment plan. A variety of pharmacological and 
non-pharmacological strategies are available to clinicians. 
Patients with less severe symptoms of depression can 
be offered nonpharmacological treatment as first-line 
therapy, e.g. cognitive behavioural therapy for depression.7 
Moderate-to-severe cases of MDD require treatment with 
antidepressant medication.
Table I: Suicide risk and protective factors
Risk factors associated with suicide
Demographic factors
Age: 15-35 years, and the elderly 
Gender: Male > female
Postpartum






Access to means, e.g. a firearm at home
Psychiatric history or illness
Psychosis, especially command-type hallucinations
Agitation and akasthisia
Depression, anxiety and panic attacks
Patient factors
Co-morbid medical illness, e.g. HIV, chronic pain and malignancy
Lack of social support
Unemployment and loss of socio-economic status
Conflict at home
Poor coping skills
Family history of suicide
Protective factors
Absence of a psychiatric illness
Employment 
Responsibility to family and children at home
Pregnancy
Strong social support
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The choice of antidepressant depends on the previous 
response to treatment and individual patient factors, e.g. 
IHD, tolerability of side-effects and affordability. Selective 
serotonin reuptake inhibitors (SSRIs) are considered to 
be first-line agents due to their tolerability and favourable 
side-effect profile. Table II indicates recommended doses 
and common side-effects. Patients who demonstrate no 
response after approximately four weeks or partial response 
after approximately six weeks should be assessed for 
adherence to treatment. The dose of the existing drug may 
Table II: Antidepressants, doses and side-effects
Class Drug 
(trade name)
Recommended dose for adults Common adverse effects Additional notes
SSRIs Citalopram 
(Celexa®, Cipramil®)
Start at 20 mg. Increase by 20 mg per 
day after one or more weeks, until desired 
efficacy is reached.
Gastrointestinal tract (nausea, 
diarrhoea and decreased appetite)
QT prolongation at doses  
≥ 40 mg.
Insomnia
Sedation and dizziness 
Sexual dysfunction





Start at 10 mg/day and increase to  
20 mg/day, if necessary.
As above No specific actions on 
hepatic CYP450 enzymes.
Fluoxetine (Prozac®) 20-40 mg daily As above Inhibits CYP450 2D6 and 
3A4.May increase agitation initially
Sertraline (Zoloft®) Start at 50 mg/day, may increase to  
100 mg/day after a week if well tolerated.
As above Maximum dose 200 mg/day.
 TCAs Amitriptyline 
(Elavil®)
Initial dose of 25 mg at bedtime. Increase 
in 25 mg increments every 3-7 days to  
150 mg/day.
 
Anticholinergic side-effects (sedation, 
dry mouth, constipation and blurred 
vision)






 SNRIs Venlafaxine 
(Effexor®, Effexor 
XR®)
Initial dose of 37.5 mg daily for a week. 
If tolerated, increase to 75 mg daily for a 
week. Increase no more than 75 mg every 
four days. Maximum of 375 mg/day.
Headaches Use with caution in cardiac 
disease.





Syndrome of inappropriate secretion 





Initial dose of 15 mg/day at bedtime. 
Increase after a week or two to  
30 mg/day. Maximum of 45 mg/day.
Anticholinergic side-effects (see TCAs) Flu-like symptoms may 
indicate low white cell count.
Useful for problematic 
insomnia, although 





Lowers white cell count (rare)
NDRIs Buproprion
(Wellbutrin®)
Start at 75 mg/day, increase to 75 mg 
twice daily after a week. Continue to 
increase in 75 mg increments if needed. 
Maximum of 300 mg/day in divided doses.
Anticholinergic side-effects (see TCAs) Seizure threshold can be 
lowered. Drug is activating. 
Useful for psychomotor 
retardation. Sexual 
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either be increased or switched to an alternative agent, 
preferably in a different class, e.g. venlafaxine (a dual 
serotonin and norepinephrine reuptake inhibitor).8 Patients 
who experience intolerable side-effects should be switched 
to an alternative agent earlier. 
Intermediate management
Ideally, patients with MDD should be followed-up within 
a week of commencing antidepressant treatment. It is 
important to enquire about and carefully document the 
side-effects of treatment, suicidal ideation and agitation. 
Treatment doses should be increased according to the 
recommended therapeutic range. In certain circumstances, 
e.g. treatment-resistant depression, referral to specialist 
psychiatric services is appropriate (Table III).
Table III: When to refer to psychiatric services
Treatment-resistant depression
Psychotic depression
Medically complicated patients with multiple co-morbidities
Actively suicidal patients
Depressed children and adolescents 
Once treatment is stabilised, the therapeutic focus falls on 
optimising global levels of function. Extended periods off 
work should be discouraged and patients should actively 
re-engage with their previous social and occupational 
activities. Although there is a surprising lack of data on how 
best to sequence medication and psychotherapy, arguably 
psychotherapy that focuses on behavioural activation and 
restructuring cognition may offer particular benefit at this 
point in treatment.
Long-term management
Most guidelines recommend that antidepressant therapy 
is continued for 6-9 months following the resolution of 
symptoms in first-episode MDD. Patients who are at 
high risk of relapse or who have experienced multiple 
episodes of depression may benefit from a longer period 
of maintenance treatment. The decision to discontinue 
treatment should be made in collaboration with the patient. 
The latter’s mood should be carefully monitored. Treatment 
should be tapered slowly and patients should be informed 
of the risk of a discontinuation syndrome. Discontinuation 
symptoms usually occur when certain medications have 
been taken for six weeks or longer and include flu-like 
illness, insomnia, nausea, balance disturbance, odd 
sensations and hyperarousal.9 
Special groups
Pregnancy
Approximately one in ten women will experience a 
depressive episode during their pregnancy or in the post-
partum period. A previous history of major depression is the 
strongest indicator of increased risk of maternal depression. 
Untreated maternal depression poses a high risk to both 
mother and infant. In some studies, it has been shown to 
result in preterm labour, lower birthweight and longer hospital 
stays.10 Exposure to antidepressants in utero, e.g. SSRIs, is 
not without risk, and has been linked to conditions such 
as persistent pulmonary hypertension in the newborn and 
a modest increase in congenital abnormalities.11 However, 
it is important to bear in mind that maternal depression has 
also been linked to foetal abnormalities in a small proportion 
of pregnant women.
An individual risk-benefit analysis should be undertaken in 
every depressed mother and a treatment plan should be 
derived in consultation with a psychiatrist or mental health 
practitioner. Treatment may include pharmacological and/
or psychological therapy, depending on the nature and 
severity of the depression. 
Older adults
Depression remains grossly underdiagnosed and 
undertreated among older adults. It is frequently overlooked 
as a possible underlying cause of the behavioural and 
psychological symptoms associated with dementia. 
Between 10-15% of community dwelling, and up to 40% 
of nursing home residents over the age of 65 years, suffer 
from major depression.12 Untreated depression in this 
group has far-reaching potential consequences, including 
premature placement in nursing homes, reduced quality of 
life, increased caregiver distress and increased morbidity 
and mortality. 
Diagnosis of major depression in older adults includes 
a thorough medical evaluation in order to exclude a 
contributory or underlying general medical condition, e.g. 
hypothyroidism, as well as a suicide-risk assessment. 
Older adults with depression are at a significantly higher 
risk of completing suicide than any other age-group with 
depression. They frequently downplay symptoms and 
suicidal ideation.13 
Clinical features of depression may differ qualitatively from 
those seen in younger people. There is greater emphasis 
on somatisation, irritability, agitation and psychomotor 
disturbance. Validated measurement tools, such as the 
Geriatric Depression Scale and the Cornell Scale for 
Depression in Dementia, may assist clinicians in assessing 
depression.14,15 SSRIs are widely accepted as a first-line 
pharmacotherapy option in late-life depression, due to their 
tolerability and favourable side-effect profile. However, even 
SSRIs may be associated with safety issues. Citalopram, 
widely used in geriatric populations, has also been 
associated with QT prolongation in doses over 40 mg per 
day. As a rule, lower initiating doses should be used with a 
slow titration and longer treatment trial. Close monitoring of 
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Children
Often, childhood depression is often a chronic, recurring 
condition that leads to significant impairments in 
psychological, scholastic and social functioning.  Between 
1-2% of children are depressed. This increases to eight per 
cent in adolescence. Several risk factors are associated with 
childhood depression, including parental psychopathology, 
rejecting or intrusive parenting, physical and sexual abuse, 
death or loss of a parent and family discord.16 
Presenting features of depression in childhood include 
sadness, irritability, aggression or behavioural disturbance, 
a detached or disinterested demeanour, and occasionally, a 
pre-occupation with death or dying. Younger children may be 
unable to quantify their feelings and may present to primary 
care practitioners with non-specific medical symptoms, e.g. 
stomach aches, headaches, nausea, cramps, bed-wetting, 
failure to thrive and behavioural disturbance. Children 
may not verbally express their emotional distress. The 
detection of childhood depression relies on the vigilance of 
the caring clinician. A number of sound psychological and 
psychopharmacological therapeutic options are available 
for the treatment of childhood depression and should be 
guided by experts in the field of child and adolescent mental 
health.
Conclusion
Depression is a common and debilitating illness, which 
may be associated with multiple medical and psychiatric 
co-morbidities. Timeous detection and evidence-based 
management that is tailored according to individual 
patient needs may significantly improve global functioning, 
morbidity and mortality.
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